Dr. Dang on Long-Term Findings of the APHINITY Trial in HER2+ Breast Cancer
January 13th 2020Chau Dang, MD, discusses the APHINITY trial, which explored the use of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) plus chemotherapy in patients with HER2-positive breast cancer.
Read More
Dr. Dang on Neratinib in Patients With HER2-Positive Breast Cancer
August 11th 2016Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential of neratinib as a combination treatment for patients with HER2-positive breast cancer.
Read More
Dr. Dang on the Significance of the MYL-1401O Biosimilar in HER2-Positive Metastatic Breast Cancer
July 26th 2016Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the significance of MYL-1401O, a proposed biosimilar of trastuzumab, as a potential treatment for patients with HER2-positive metastatic breast cancer.
Read More